Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 12:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 372 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer Related Lymphedema, Covid19
Interventions
Survey
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Vaccination, Wastewater Surveillance
Interventions
Wastewater vaccine prompts
Behavioral
Lead sponsor
Syracuse University
Other
Eligibility
Not listed
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Syracuse, New York
Conditions
Covid19, Vaccine Acceptability
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
1,208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Coronavirus Infection
Interventions
INO-4800, CELLECTRA® 2000
Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Lexington, Kentucky • Kansas City, Missouri • Philadelphia, Pennsylvania
Conditions
COVID-19
Interventions
mRNA-CR-04 vaccine 10μg, mRNA-CR-04 vaccine 30μg, mRNA-CR-04 vaccine 100μg, Placebo, mRNA-CR-04 vaccine 3μg
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
San Diego, California • Melbourne, Florida • Peoria, Illinois + 1 more
Conditions
Type 2 Diabetes, Heart Failure, Reduced Ejection Fraction
Interventions
Ketone Monoester (KE)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
Biological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg, BNT162b2 30mcg, Placebo, Biological/Vaccine: BNT162b2 3mcg
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
6 Months to 15 Years
Enrollment
11,837 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
90
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 67 more
Conditions
SARS-CoV2, COVID-19
Interventions
VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years and older
Enrollment
5,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
145
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 126 more
Conditions
Healthy Volunteers
Interventions
AdCOVID, Placebo
Biological · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
6
States / cities
Hialeah, Florida • Melbourne, Florida • Peoria, Illinois + 3 more
Not listed No phase listed Observational Accepts healthy volunteers

(VIII): The Eight Study and Immunologic Response Sub-study

NCT05237024
Conditions
Vaccine Reaction
Interventions
Not listed
Lead sponsor
physIQ, Inc.
Industry
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
COVID-19, Infectious Disease
Interventions
JCXH-221, Placebo
Biological · Other
Lead sponsor
Immorna Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
4
States / cities
Hallandale, Florida • Savannah, Georgia • Lincoln, Nebraska + 1 more
Conditions
Inflammatory Bowel Diseases
Interventions
Influenza vaccine, COVID-19 vaccine
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 64 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals

NCT05997290
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2)
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
12 Years and older
Enrollment
1,051 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
37
States / cities
Athens, Alabama • Huntsville, Alabama • Mobile, Alabama + 30 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines

NCT05973006
Conditions
COVID-19
Interventions
NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
Biological
Lead sponsor
Novavax
Industry
Eligibility
11 Years to 18 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
20
States / cities
Davie, Florida • Jacksonville, Florida • Miami, Florida + 17 more
Conditions
Myocardial Injury, COVID-19, Vaccine Reaction
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
COVID-19, Immunosuppression, Vaccine Response Impaired
Interventions
Reduction in antimetabolite immunosuppression
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Conditions
Influenza, COVID-19
Interventions
Influenza and COVID-19 Combination A, Licensed influenza vaccine, COVID-19 Vaccine, Influenza and COVID-19 Combination B, Placebo, Investigational influenza vaccine
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 64 Years
Enrollment
8,795 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
106
States / cities
Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 76 more
Conditions
Influenza, COVID-19, Vaccination Hesitancy
Interventions
Text message influenza vaccine reminders, Text message COVID-19 vaccine reminders, Text message influenza and COVID-19 vaccine reminders
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
6 Months to 17 Years
Enrollment
66,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Itasca, Illinois • New York, New York • Philadelphia, Pennsylvania
Conditions
Vaccine Preventable Disease
Interventions
Educational, culturally appropriate COVID-19 messages
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 101 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
COVID-19, Vaccine
Interventions
REDES, Control
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years and older
Enrollment
3,317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
62
States / cities
Birmingham, Alabama • Tucson, Arizona • Garden Grove, California + 51 more
Conditions
Multiple Sclerosis, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Diseases, Autoimmune Diseases, Immune System Diseases, Pathologic Processes
Interventions
Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test, T-Detect COVID T-cell blood test
Device
Lead sponsor
Dragonfly Research, LLC
Other
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Wellesley, Massachusetts
Conditions
Relapsing Multiple Sclerosis
Interventions
Ofatumumab, Covid-19 vaccine
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Phoenix, Arizona • Owosso, Michigan • St Louis, Missouri + 1 more